Patents Examined by Niloofar Rahmani
  • Patent number: 11981674
    Abstract: Compounds for treating preventing malaria and, particularly, to larvicidal agents that are 7-isopropyl 1-ethyl/methyl 3-(substituted benzoyl)-2-substituted indolizine-1,7-dicarboxylates derivatives and their use as larvicidal agents.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Sandeep Chandrashekharappa, Pran Kishore Deb, Osama I. Alwassil, Rashmi Venugopala
  • Patent number: 11981673
    Abstract: Novel 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7-tricarboxylates compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 7-isopropyl 1,2-dimethyl 3-(substituted benzoyl)indolizine-1,2,7-tricarboxylates compounds, identified as adenosine A3 receptor (A3AR) modulators, are useful as anti-inflammation, anticancer and/or anti-ischemic agents, and as agents for treating other adenosine overexpression related conditions including rheumatoid arthritis, psoriasis and fatty liver diseases, inflammation, pain, and number of pathological conditions of the central and peripheral nervous systems.
    Type: Grant
    Filed: October 6, 2023
    Date of Patent: May 14, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Buccioni Michela, Gabriella Marucci, Sandeep Chandrashekharappa, Rashmi Venugopala
  • Patent number: 11981657
    Abstract: This application relates to substituted benzimidazoles, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application is also related to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasms, including tumors and/or cancers.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: May 14, 2024
    Assignee: EPIGENETIX, INC.
    Inventors: Mehrnaz Pourashraf, Guillaume Jacquemot, Stephen Claridge, Malken Bayrakdarian, Shawn Johnstone, Jeffrey S. Albert, Andrew Griffin
  • Patent number: 11976066
    Abstract: Compounds for treating tuberculosis and, particularly, to anti-tubercular compounds that are substituted 7-amino-3-(substituted benzoyl)indolizine-1-carboxylates and their use as anti-tubercular agents.
    Type: Grant
    Filed: October 23, 2023
    Date of Patent: May 7, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Melendran Pillay, Vijaykumar Uppar, Pran Kishore Deb, Rashmi Venugopala, Sandeep Chandrashekharappa, Basavaraj Padmashali
  • Patent number: 11970495
    Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: April 30, 2024
    Assignee: KIND PHARMACEUTICAL
    Inventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
  • Patent number: 11969412
    Abstract: The invention provides a p38 MAPK inhibitor of Formula I, or a pharmaceutically acceptable salt or solvate thereof: for use in the treatment or prevention of hypercytokinemia in a human patient; wherein R is C1-3alkyl, optionally substituted by one or more halo, NR1R2 or hydroxy, and R1and R2 are independently H, halo or C1-3alkyl, optionally substituted by one or more F. Also provided are compositions for use in the treatment or prevention of hypercytokinemia comprising the p38 MAPK inhibitor of Formula I; and methods for treating or preventing hypercytokinemia in a human patient in need thereof comprising administering to the patient a therapeutically or prophylactically effective amount of a p38 MAPK inhibitor of Formula I. The invention also provides a p38 MAPK inhibitor and an antimicrobial agent, such as an antiviral agent, for use in the treatment or prevention of hypercytokinemia.
    Type: Grant
    Filed: September 23, 2022
    Date of Patent: April 30, 2024
    Assignee: Poolbeg Pharma (UK) Limited
    Inventors: Adrian Huw Davies, Pui-Man Choy, Vinay Saunders, Basma Bahsoun, Surender Vashist, Neil Edward Torbett, Paul Andrew Whittaker
  • Patent number: 11970493
    Abstract: The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for inhibiting ATX. Also provided are methods of preparing said compounds and compositions, and synthetic precursors of said compounds.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 30, 2024
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Sung-Ku Choi, Yoon-Suk Lee, Sung-Wook Kwon, Kyung-Sun Kim, Jeong-Geun Kim, Jeong-Ah Kim, An-Na Moon, Sun-Young Park, Jun-Su Ban, Dong-Keun Song, Kyu-Sic Jang, Ju-Young Jung, Soo-Jin Lee
  • Patent number: 11957689
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
    Type: Grant
    Filed: October 5, 2022
    Date of Patent: April 16, 2024
    Assignee: Teon Therapeutics, Inc.
    Inventors: Elfatih Elzein, Jiwen Liu
  • Patent number: 11951105
    Abstract: The present disclosure relates to methods of initiating brexpiprazole treating in patients with schizophrenia or major depressive disorder. The present disclosure further relates to modified dosing regimens for obese patients and/or patients that are CYP2D6 poor metabolizers. In embodiments, the modified dosing regimens administers double the daily dose while initiating treatment.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: April 9, 2024
    Assignee: LAKE O'HARA LLC
    Inventors: Sundar Srinivasan, Christina Chow Wallen
  • Patent number: 11952342
    Abstract: The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.
    Type: Grant
    Filed: May 1, 2023
    Date of Patent: April 9, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow
  • Patent number: 11952378
    Abstract: Novel pyrrolo[2,3-c]isoquinoline-1,2-dione, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[2,3-c]isoquinoline-1,2-dione compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
    Type: Grant
    Filed: December 14, 2023
    Date of Patent: April 9, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Christophe Tratrat, Michelyne Haroun
  • Patent number: 11945817
    Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
    Type: Grant
    Filed: April 10, 2023
    Date of Patent: April 2, 2024
    Assignee: KIND PHARMACEUTICAL
    Inventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
  • Patent number: 11944622
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
    Type: Grant
    Filed: July 13, 2022
    Date of Patent: April 2, 2024
    Assignee: Annapurna Bio, Inc.
    Inventors: Haifeng Tang, Michael Hanson, Sarah Boyce, Zhe Nie
  • Patent number: 11939292
    Abstract: The present invention is directed to novel chemical compositions of matter and their methods of synthesis, and in particular novel analogs of Psilocin having enhanced physical and pharmacokinetic characteristics.
    Type: Grant
    Filed: November 1, 2023
    Date of Patent: March 26, 2024
    Assignee: Mydecine Innovations Group Inc.
    Inventors: Denton W. Hoyer, Robert F. Roscow
  • Patent number: 11932618
    Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: March 19, 2024
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
  • Patent number: 11926592
    Abstract: Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: March 12, 2024
    Assignee: Amgen Inc.
    Inventors: Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Alisa Golightly
  • Patent number: 11926626
    Abstract: This disclosure relates to GLP-1 agonists of Formula (I), including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same.
    Type: Grant
    Filed: September 21, 2022
    Date of Patent: March 12, 2024
    Assignee: Gasherbrum Bio, Inc.
    Inventors: Qinghua Meng, Weiqiang Xing, Haizhen Zhang, Xichen Lin, Hui Lei, Andrew Jennings
  • Patent number: 11919898
    Abstract: A crystal form of an azaindole derivative and a preparation method thereof are disclosed.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: March 5, 2024
    Assignee: SHENZHEN LINGFANG BIOTECH CO., LTD.
    Inventors: Zhengxia Chen, Meibi Dai, Yang Zhang
  • Patent number: 11919878
    Abstract: An 9-(2-hydroxypyridin-3-yl)-10-(2-phenyletnyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: March 5, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11919900
    Abstract: Compounds for treating tuberculosis and, particularly, antitubercular compounds that are 1-substituted benzoyl-4-bromopyrrolo[1,2-a]quinoline-3-carboxylate derivatives and their use as antitubercular agents are provided.
    Type: Grant
    Filed: August 21, 2023
    Date of Patent: March 5, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Katharigatta N. Venugopala, Pran Kishore Deb, Melendran Pillay, Sandeep Chandrashekharappa, Mohamed A. Morsy, Bandar E. Aldhubiab, Mahesh Attimarad, Anroop B. Nair, Nagaraja Sreeharsha, Vijaykumar Uppar, Raghu Prasad Mailavaram, Basavaraj Padmashali